drugset / Trial / NCT03537950

Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder

NCT03537950 ↗

Completed 38 enrolled King's College London
RandomizedCrossoverDouble-blindBasic science

Summary

This study investigates brain response to single acute dose of cannabidiol, cannabidivarin, and placebo in healthy men with and without autism spectrum disorder

Timeline

Start
2016-08-22
Primary completion
2017-02-16
Completion
2017-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CBD Unknown 600 mg Oral
Subject Cannabidivarin Small molecule 600 mg Oral